Literature DB >> 29411341

Does IGF-1 play a role in the biology of ovarian cancer?

Dominika Majchrzak-Baczmańska1, Andrzej Malinowski, Ewa Głowacka, Miłosz Wilczyński.   

Abstract

OBJECTIVES: The aim of the study was to investigate serum concentrations of the insulin-like growth factor-1 in women with ovarian cancer and healthy controls, and to compare free IGF-1 levels with selected clinical and pathological param-eters. Correlation analysis was used to measure the following: IGF-1 concentration and Ca125; IGF-1 level and the height of the OC patients.
MATERIAL AND METHODS: The study included 70 patients with OC and 50 healthy controls. Serum concentrations of free IGF-1 were measured in all subjects. Routine diagnostic tests (CBC and USG and Ca125) were performed.
RESULTS: Significantly higher serum concentrations of free IGF-1 were found in the study group as compared to controls. No statistically significant relationships between IGF-1 serum concentrations and tumor differentiation, histological type, and disease stage were detected. No statistically significant correlations between IGF-1 and Ca125 level or between IGF-1 and growth of OC patients were found.
CONCLUSIONS: Serum IGF-1 participates in the etiopathogenesis of ovarian cancer in menstruating women, while local synthesis of this factor and other components of the autocrine loop of the IGF-1 system play a greater role in their post-menopausal peers.

Entities:  

Keywords:  carcinogenesis; insulin-like growth factor–1; ovarian cancer

Mesh:

Substances:

Year:  2018        PMID: 29411341     DOI: 10.5603/GP.a2018.0003

Source DB:  PubMed          Journal:  Ginekol Pol        ISSN: 0017-0011            Impact factor:   1.232


  3 in total

1.  MLLT11-TRIL complex promotes the progression of endometrial cancer through PI3K/AKT/mTOR signaling pathway.

Authors:  Jingnan Liao; Huan Chen; Mingming Qi; Jinjin Wang; Mingyuan Wang
Journal:  Cancer Biol Ther       Date:  2022-12-31       Impact factor: 4.742

2.  Pan-Cancer Analysis of IGF-1 and IGF-1R as Potential Prognostic Biomarkers and Immunotherapy Targets.

Authors:  Yinqi Zhang; Chengqi Gao; Fei Cao; Ying Wu; Shuanggang Chen; Xue Han; Jingqin Mo; Zhiyu Qiu; Weijun Fan; Penghui Zhou; Lujun Shen
Journal:  Front Oncol       Date:  2021-11-05       Impact factor: 6.244

3.  NOX4 Signaling Mediates Cancer Development and Therapeutic Resistance through HER3 in Ovarian Cancer Cells.

Authors:  Wen-Jing Liu; Ying-Xue Huang; Wei Wang; Ye Zhang; Bing-Jie Liu; Jian-Ge Qiu; Bing-Hua Jiang; Ling-Zhi Liu
Journal:  Cells       Date:  2021-06-30       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.